Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD8601 epicardial injections during CABG in stable coronary artery disease with reduced LVEF
NL-OMON49505Phase 2Withdrawn
- Sponsor
- AstraZeneca
- Start
- Nov 2018
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AZD-8601 in coronary arteriosclerosis and heart failure (HF) (3 arms), sponsored by AstraZeneca. Primary endpoints: Safety and tolerability of AZD8601 following epicardial injection during CABG, Adverse events and serious adverse events and 5 more. Planned start Nov 2018; status: withdrawn.
02
Drugs
AZD-8601
03
Conditions
coronary arteriosclerosisheart failure (HF)
Beyond the preview
Go deeper on NL-OMON49505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49505.